FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

The FDA approved a supplemental application for CABLIVI (caplacizumab) from Genzyme, authorizing changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

SUPPL AP for CABLIVI (CAPLACIZUMAB)